Open AccessSGLT2 inhibition potentiates the cardiovascular, renal, and metabolic effects of sGC stimulation in hypertensive rats with prolonged exposure to high-fat diet
Author(s) -
Virginia Reverte,
Francisca Rodríguez,
Lidia Oltra,
Juan Manuel Moreno,
María T. Llinás,
Courtney Shea,
Chad D. Schwartzkopf,
Emmanuel Buys,
Jaime L. Masferrer,
Francisco Salazar
Publication year - 2022
Publication title -
american journal of physiology. heart and circulatory physiology
Language(s) - English
Resource type - Journals
eISSN - 1522-1539
pISSN - 0363-6135
DOI - 10.1152/ajpheart.00386.2021
Subject(s) - empagliflozin , medicine , endocrinology , renal function , insulin resistance , leptin , creatinine , kidney , blood pressure , insulin , diabetes mellitus , type 2 diabetes , obesity
This is the first study, to our knowledge, showing that SGLT2 inhibition potentiates the beneficial cardiovascular, renal, and metabolic effects elicited by sGC stimulation in hypertensive rats with prolonged high-fat diet. The effects of the simultaneous administration of praliciguat and empagliflozin are greater than those elicited by either one alone. The effects of the simultaneous treatment may be related to a greater reduction in the inflammatory status.